Funded Startups in Plan-les-ouates
In Plan-les-ouates, the largest disclosed round in the 10 most recent entries is spineart’s $23M on 2024-03-18, which is far above the rest of the disclose…
In Plan-les-ouates, the largest disclosed round in the 10 most recent entries is spineart’s $23M on 2024-03-18, which is far above the rest of the disclosed amounts shown (the next-highest disclosed figure is Calypso Biotech’s $10M on 2021-09-09; multiple other rounds are in the $200K–$4M range, with several at $100K and $110K). The list also shows a tight temporal cluster: four of the 10 rounds were disclosed between 2023-09-20 and 2023-03-16, and the most recent entry (spineart, 2024-03-18) sits just after that 2023 concentration.
Sector concentration is pronounced in Biotechnology, which appears in four entries (MPC Therapeutics on 2023-11-16 at $110K; Addex Therapeutics on 2023-09-20 at $4M; Calypso Biotech on 2021-09-09 at $10M; Adiposs on 2021-06-03 at $100K). By stage labeling, five of the 10 rows use “Series Unknown,” while two are explicitly labeled (Calypso Biotech as Series A on 2021-09-09 and Exomotion as Grant on 2021-09-24), and one row (spineart) has no series label.
Most recent rounds
10 shownRelated listings
Frequently asked
What stands out on deal size in Plan-les-ouates, and is the distribution concentrated or broad?
The disclosed-size distribution is dominated by spineart’s $23M round on 2024-03-18; it’s substantially larger than the next-highest disclosed amount, Calypso Biotech’s $10M on 2021-09-09. Several other disclosed amounts sit well below $4M (e.g., Addex Therapeutics $4M on 2023-09-20; MPC Therapeutics $110K on 2023-11-16).
Is there a noticeable date cluster in the most recent 10 rounds, or are they spread out evenly?
They cluster heavily in 2023: Addex Therapeutics ($4M, 2023-09-20), Imverse ($440K, 2023-06-15), Endotelix ($100K, 2023-03-16), and Plair SA ($320K, 2023-03-16) all fall within that window. The earliest disclosed date in the 10 rows is 2020-06-08 (Mikajaki $2M), creating a longer tail behind the 2023 activity.
Which sectors appear most often in this city-based list?
Biotechnology appears in four of the 10 entries (MPC Therapeutics $110K on 2023-11-16; Addex Therapeutics $4M on 2023-09-20; Calypso Biotech $10M on 2021-09-09; Adiposs $100K on 2021-06-03). Health Care shows up in three entries (spineart $23M on 2024-03-18; Endotelix $100K on 2023-03-16; Mikajaki $2M on 2020-06-08).
How much of the activity is hard to classify by stage label in these rows?
Stage labeling is incomplete: five of the 10 rows are marked “Series Unknown” (e.g., MPC Therapeutics on 2023-11-16 at $110K; Addex Therapeutics on 2023-09-20 at $4M; Imverse on 2023-06-15 at $440K; Plair SA on 2023-03-16 at $320K; Adiposs on 2021-06-03 at $100K). Two rows are explicitly labeled (Calypso Biotech as Series A on 2021-09-09 at $10M; Exomotion as Grant on 2021-09-24 at $200K).
Are there outliers by geography or by sector mix compared with the rest of the page?
Geography is consistent: all 10 rows list Plan-les-ouates, Geneve, Switzerland as the location. The clearest outlier is size rather than geography or mix: spineart’s $23M (2024-03-18, Health Care) is far above the majority of smaller disclosed rounds in the table (e.g., multiple entries at $100K, plus Calypso Biotech at $10M).
Which rounds closed nearest to the latest date shown, and what does that say about recent momentum?
The latest disclosed round is spineart on 2024-03-18 ($23M). The next most recent labeled rows behind it are MPC Therapeutics on 2023-11-16 ($110K) and Addex Therapeutics on 2023-09-20 ($4M), followed by Imverse on 2023-06-15 ($440K), indicating that most disclosed activity in this snapshot clusters within 2023 leading up to the 2024 entry.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.